Immunocore Holdings Net Worth

Immunocore Holdings Net Worth Breakdown

  IMCR
The net worth of Immunocore Holdings is the difference between its total assets and liabilities. Immunocore Holdings' net worth represents the value of the company's equity or ownership interest. In other words, it is the amount of money that would be left over if all of Immunocore Holdings' assets were sold and all of its debts were paid off. Net worth is sometimes referred to as shareholder's equity or book value. Immunocore Holdings' net worth can be used as a measure of its financial health and stability which can help investors to decide if Immunocore Holdings is a good investment. It is also essential in determining the company's creditworthiness and ability to secure financing before investing in Immunocore Holdings stock.

Immunocore Holdings Net Worth Analysis

Immunocore Holdings' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Immunocore Holdings' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Immunocore Holdings' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Immunocore Holdings' net worth analysis. One common approach is to calculate Immunocore Holdings' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Immunocore Holdings' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Immunocore Holdings' net worth. This approach calculates the present value of Immunocore Holdings' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Immunocore Holdings' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Immunocore Holdings' net worth. This involves comparing Immunocore Holdings' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Immunocore Holdings' net worth relative to its peers.
To determine if Immunocore Holdings is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Immunocore Holdings' net worth research are outlined below:
The company reported the previous year's revenue of 310.2 M. Net Loss for the year was (51.09 M) with profit before overhead, payroll, taxes, and interest of 299.7 M.
Immunocore Holdings has a poor financial position based on the latest SEC disclosures
Over 94.0% of the company shares are owned by institutional investors
Immunocore Holdings uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Immunocore Holdings. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Immunocore Holdings' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
6th of March 2024
Upcoming Quarterly Report
View
8th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Follow Immunocore Holdings' market capitalization trends

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.44 B.

Project Immunocore Holdings' profitablity

The company has Profit Margin (PM) of (0.16) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.02) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.02.
When accessing Immunocore Holdings' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Immunocore Holdings' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Immunocore Holdings' profitability and make more informed investment decisions.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Immunocore Holdings insiders, such as employees or executives, is commonly permitted as long as it does not rely on Immunocore Holdings' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Immunocore Holdings insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Baker Bros. Advisors Lp few days ago
Disposition of tradable shares by Baker Bros. Advisors Lp of Immunocore Holdings subject to Rule 16b-3
 
Travis Coy over two months ago
Acquisition by Travis Coy of 274033 shares of Immunocore Holdings at 29.5 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Baker Bros. Advisors Lp over three months ago
Discretionary transaction by Baker Bros. Advisors Lp of 674261 shares of Immunocore Holdings subject to Rule 16b-3
 
Herbst Roy Steven over six months ago
Disposition of 8676 shares by Herbst Roy Steven of Immunocore Holdings at 58.69 subject to Rule 16b-3
 
Berman David M over six months ago
Disposition of 28553 shares by Berman David M of Immunocore Holdings at 17.46 subject to Rule 16b-3
 
Baker Bros. Advisors Lp over six months ago
Discretionary transaction by Baker Bros. Advisors Lp of 1449226 shares of Immunocore Holdings subject to Rule 16b-3
 
Bell John Irving over six months ago
Acquisition by Bell John Irving of 14534 shares of Immunocore Holdings at 50.47 subject to Rule 16b-3
 
St Leger Tina Amber over six months ago
Disposition of 4375 shares by St Leger Tina Amber of Immunocore Holdings at 64.06 subject to Rule 16b-3
 
Bahija Jallal over a year ago
Acquisition by Bahija Jallal of 281819 shares of Immunocore Holdings at 70.5 subject to Rule 16b-3
 
Bell John Irving over a year ago
Immunocore Holdings exotic insider transaction detected
Immunocore Holdings time-series forecasting models is one of many Immunocore Holdings' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Immunocore Holdings' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Immunocore Holdings Earnings per Share Projection vs Actual

Immunocore Holdings Corporate Management

Tina LegerExecutive OfficerProfile
Sbastien DesprezHead CommunicationsProfile
Debra NielsenChief StaffProfile
JD EsqChief OfficerProfile
Annelise VuidepotCTO ResearchProfile
Brian MBACFO StrategyProfile
Amy JudgePreinChief OfficerProfile

Additional Tools for Immunocore Stock Analysis

When running Immunocore Holdings' price analysis, check to measure Immunocore Holdings' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunocore Holdings is operating at the current time. Most of Immunocore Holdings' value examination focuses on studying past and present price action to predict the probability of Immunocore Holdings' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunocore Holdings' price. Additionally, you may evaluate how the addition of Immunocore Holdings to your portfolios can decrease your overall portfolio volatility.